Amicus grabs Dimerix’s rare kidney disease drug for $30M upfront
Amicus Therapeutics has paid $30 million cash upfront to license US rights to a late-stage therapy for a rare kidney disease from the Australian biotech Dimerix. The deal provides for milestone payments of $560 million ...
Amicus Therapeutics has paid $30 million cash upfront to license US rights to a late-stage therapy for a rare kidney disease from the Australian biotech Dimerix.
The deal provides for milestone payments of $560 million ...
